Antitumor and normal cell protective effect of PKC412 in the athymic mouse model of ovarian cancer

Annals of Clinical and Laboratory Science

Volumn 36, Issue 4, 2006, Pages 455-460

  Kim, Myungshin ^a   Park, In Yang ^a   Lim, Jihyang ^a   Kim, Yonggoo ^a   Han, Ku Taek ^a   Chung, Won Heui ^a   Han, Kyungja ^a,b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Cytokine; Ovarian cancer; Paclitaxel; PKC412; Protein kinase C inhibitor

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; N BENZOYLSTAUROSPORINE; PACLITAXEL; PLACEBO; PROTEIN KINASE C INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPSY; BODY WEIGHT; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROTECTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; WEIGHT REDUCTION;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CELL LINE, TUMOR; CYTOKINES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; OVARIAN NEOPLASMS; PACLITAXEL; PROTEIN KINASE C; SPLEEN; STAUROSPORINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 33751243969     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Cannistra SA. Cancer of the ovary. NEJM 1993;329:1550-1559.
2. Hu L, Hofmann J, Zaloudek C, Ferrara N, Hamilton T, Jaffe RB. Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 2002;161:1917-1924.
3. Bhatt V, Saleem A. Review: Drug-induced neutropenia-pathophysiology, clinical features, and management. Ann Clin Lab Sci 2004;34:131-137.
4. Monnerat C, Henriksson R, Le Chevalier T, Novello S, Berthaud P, Faivre S, Raymond E. Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemicitabine and cisplatin in patients with non-small-cell lung cancer. Ann Oncol 2004;15:316-323.
5. Fabbro D, Ruetz S, Bodis S, Pruschy M, Csermak K, Man A, Campochiaro P, Wood J, O'Reilly T, Meyer T. PKC412-a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 2000;15:17-28.
6. Baran J, Kowalczyk D, Ozog M, Zembala M. Three-color flow cytometry detection of intracellular cytokines in peripheral blood mononuclear cells: comparative analysis of phorbol myristate acetate-ionomycin and phytohemagglutinin stimulation. Clin Diagn Lab Immunol 2001;8:303-313.
7. Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer. Am J Pathol 1998;153:1249-1256.
8. Teicher BA, Menon K, Alvarez E, Shin C, Faul MM. Antiangiogenic and antitumor effects of a protein kinase Cβ inhibitor in human breast cancer and ovarian cancer xenografts. Invest New Drugs 2002;20:241-251.
9. Fabbro D, Buchdunger E, Wood J, Mestan J, Hofmann F, Ferrari S, Mett H, O'Reilly T, Meyer T. Inhibitors of protein kinase: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. Pharmacol Ther 1999;82:293-301.
10. Blagosklonny MV, Pardee S. Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res 2001;61:4301-4305.
11. Chen X, Lowe M, Herliczek T, Hall MJ, Danes C, Lawrence DA, Keyomarsi K. Protection of normal proliferating cells against chemotherapy by staurosporine-mediated, selective, and reversible G1 arrest. J Natl Cancer Inst 2000;92:1999-2008.
12. Thavasu P, Propper D, McDonald A, Dobbs N, Ganesan T, Talbot D, Braybrook J, Caponigro F, Hutchison C, Twelves C, Man A, Fabbro D, Harris A, Balkwill F. The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients. Cancer Res 1999;59:3980-3984.
13. Si M-S, Reitz BA, Borie RD. Effects of the kinase inhibitor CGP41251 (PKC412) on lymphocyte activation and TNF-α production. Int Immunopharmacol 2005;5:1141-1149.
14. Alkan SS, Rutschmann S, Grogg D, Erb P. Effects of a new protein kinase C inhibitor CGP 41251 on T cell functions: Inhibition of activation, growth, and target cell killing. Cell Immunol 1993;150:137-148.